A Guide to Drug Therapy in Patients with Enteral Feeding Tubes: Dosage Form Selection and Administration Methods

Hospital Pharmacy

Volumn 39, Issue 3, 2004, Pages 225-237

  Beckwith, M Christina ^a   Feddema, Sarah S ^a   Barton, Richard G ^b   Graves, Caran ^a  

^a UNIVERSITY OF UTAH HOSPITAL   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Critical care; Drug administration; Enteral nutrition

Indexed keywords

CIPROFLOXACIN; COLESTYRAMINE; CROMOGLYCATE DISODIUM; DILTIAZEM; DRUG VEHICLE; ESOMEPRAZOLE; FERROUS GLUCONATE; GASTROCOM; ISPAGULA; KREON; LACTOSE; LANSOPRAZOLE; LAXATIVE; LEVOFLOXACIN; MANNITOL; NIZATIDINE; OMEPRAZOLE; PANCREAS ENZYME; PANCREASE MT; PANCRELIPASE; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RABEPRAZOLE; SACCHARIN; SORBITOL; SUCROSE; SWEETENING AGENT; THEOPHYLLINE; UNINDEXED DRUG; VERAPAMIL; VITAMIN K GROUP; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL DISTENSION; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG COMPETITION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG INCOMPATIBILITY; ENTERIC FEEDING; FEEDING APPARATUS; FOOD DRUG INTERACTION; GASTROINTESTINAL TRACT; HOSPITAL PATIENT; HUMAN; HYPEROSMOLALITY; INTENSIVE CARE; NUTRITION; NUTRITIONAL SUPPORT; OBSTRUCTION; OSMOLALITY; PARENTERAL NUTRITION; PRACTICE GUIDELINE; REVIEW; TUBE FEEDING; TUBE OBSTRUCTION; VOMITING;

EID: 1542358075     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870403900308     Document Type: Review

References (62)

1. Rollins CJ. Adult enteral nutrition. In: Koda-Kimble MA et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 6th ed. Vancouver: Applied Therapeutics; 1995, 34.1-28.
2. Belknap DC, et al. Administration of medications through enteral feeding catheters. Am J Crit Care. 1997;6(5):382-92.
3. Silberman H. Parenteral and Enteral Nutrition. 2nd ed. Norwalk, CT: Appleton & Lange; 1989, 117-58.
4. Rombeau JL, Caldwell MD, eds. In: Clinical Nutrition: Enteral and Tube Feeding. 2nd ed. Philadelphia, PA: WB Saunders; 1990.
5. Estoup M. Approaches and limitations of medication delivery in patients with enteral feeding tubes. Crit Care Nurse. 1994;14:68-72,79.
6. Gora ML, et al. Considerations of drug therapy in patients receiving enteral nutrition. Nutr Clin Pract 1989;4:105-10.
7. Klein S, Fleming CR. Enteral and parenteral nutrition. In: Sleisenger MG, et al, eds. Gastrointestinal Disease: Pathophysiology Diagnosis Management. 5th ed. Philadelphia, PA: WB Saunders; 1993, 2062-96.
8. Schuffler MD, Sinanan MN. Intestinal obstruction and pseudo-obstruction. In: Sleisenger MH, et al, eds. Gastrointestinal Disease: Pathophysiology Diagnosis Management. 5th ed. Philadelphia: WB Saunders; 1993, 898-916.
9. Thomson FC, et al. Managing drug therapy in patients receiving enteral and parenteral nutrition. Hosp Pharmacist. 2000;7:155-64.
10. Gilbar PJ. A guide to enteral drug administration in palliative care. J Pain Symptom Manage. 1999;17:197-207.
11. Rombeau JL, Caldwell MD, eds. Clinical Nutrition: Enteral and Tube Feeding. 3rd ed. Philadelphia, PA: WB Saunders; 1997.
12. Janson DD, Chessman KH. Enteral nutrition. In: DiPiro JT et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: McGraw-Hill; 2002, 2495-517.
13. Mitchell JF. Oral dosage forms that should not be crushed or chewed. Hosp Pharm. 2002;37:213-14.
14. Personal communication. Whitehouse Station, NJ: Merck; 1994.
15. AHFS Drug Information 2002. Bethesda, MD: American Society of Health-System Pharmacists; 2002.
16. Personal communication. Lake Forest, IL: TAP Pharmaceuticals; 1996.
17. Nexium (esomeprazole) [package insert]. Wilmington, DE: AstraZeneca; 2001.
18. Aciphex (rabeprazole sodium) delayed-release tablets package insert. Teaneck, NJ: Eisai Pharmaceuticals; 2000.
19. Protonix (pantoprazole sodium) delayed-release tablets [package insert]. Philadelphia, PA: Wyeth; 2001.
20. Sharma VK, et al. Oral pharmacokinetics of omeprazole and lansoprazole after single and repeated doses as intact capsules or as suspensions in sodium bicarbonate. Aliment Pharmacol Ther. 2000;14:887-92.
21. Song JC, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Am J Health Syst Pharm. 2001;58:689-94.
22. Sharma VK, et al. Simplified lansoprazole suspension - a liquid formulation of lansoprazole-effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol. 1999;94:1813-7.
23. Zimmermann A, et al. Alternative methods of proton-pump inhibitor administration. Consult Pharm. 1997;12:990-8.
24. Phillips JO, et al. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med. 1996;24:1793-800.
25. Omeprazole nasogastric administration (Drug Consult). In: Hutchison TA, Shahan DR, eds. Drugdex System. Greenwood Village, CO: Micromedex. (Edition expires September 30, 2002).
26. Prevacid (lansoprazole) delayed-release capsules and Prevacid (lansoprazole) for delayed-release oral suspension [package insert]. Lake Forest, IL: TAP Pharmaceuticals; 2002.
27. Safety briefs. ISMP Medication Safety Alert! 2002;7(12):1-2.
28. Product reference guide. Deerfield, IL: Nestle Clinical Nutrition; 2001.
29. Hutchison TA, Shahan DR, eds. Drugdex System. Greenwood Village, CO: Micromedex (Edition expires September 30, 2002).
30. Dickerson RN, Melnik G. Osmolality of oral drug solutions & suspensions. Am J Hosp Pharm. 1988;45:832-34.
31. Jew RK, et al. Osmolality of commonly used medications and formulas in the neonatal intensive care unit. Nutr Clin Pract. 1997;12:158-63.
32. Sterile water for injection. In: USP24/NF 19 The United States Pharmacopeia/The National Formulary. Rockville, MD: United States Pharmacopeial Convention; 1999, 1753.
33. Klang MG. Medicating tube-fed patients. Nursing. 1996;26:18.
34. Lutomski DM, et al. Sorbitol content of selected oral liquids. Ann Pharmacother. 1993;27:269-74.
35. Burns PE, et al. Physical compatibility of enteral formulas with various common medications. J Am Diet Assoc. 1988;88:1094-6.
36. Cutie AJ, et al. Compatibility of enteral products with commonly employed drug additives. JPEN J Parenter Enter Nutr. 1983;7:186-91.
37. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurol. 1982;32:570-2.
38. Kutsop JJ. Update on vitamin K1 content of enteral products [letter]. Am J Hosp Pharm. 1984;41:1762.
39. Landau J, Moulds RFW. Warfarin resistance caused by vitamin K in intestinal feeds [letter]. Med J Aust. 1982;263-4.
40. Watson AJM, et al. Enteral feeds may antagonise warfarin. BMJ. 1984;288:557.
41. Parr MD, et al. Effect of enteral nutrition on warfarin therapy [letter]. Clin Pharm. 1982;1:274-6.
42. Healy DP, et al. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother. 1996;40:6-10.
43. de Marie S, et al. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med. 1998;24:343-6.
44. Wright DH, et al. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. JPEN J Parenter Enter Nutr. 2000;24:42-8.
45. Cohn SM, et al. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother. 1996;38:871-6.
46. Mueller BA, et al. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother. 1994;38:2101-5.
47. Mimoz O, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med. 1998;24:1047-51.
48. Cipro (ciprofloxacin) and enteral nutrition [written communication]. West Haven, CT: Bayer; 2001.
49. Drug Facts and Comparisons. St. Louis, MO: Facts & Comparisons; 2002.
50. Crushing tables/enteral feeds - Levaquin (levofloxacin) [written communication]. Raritan, NJ: Ortho-McNeil; 2001.
51. Cipro (ciprofloxacin) [package insert]. West Haven, CT: Bayer; 2000.
52. Cipro (ciprofloxacin) oral suspension [written communication]. West Haven, CT: Bayer; 2002.
53. Marcuard SP, et al. Clearing obstructed feeding tubes. JPEN J Parenter Enter Nutr. 1989;13:81-3.
54. Bommarito AA, et al. A new approach to the management of obstructed enteral feeding tubes. Nutr Clin Pract. 1989;4:111-4.
55. Bailey K. Management of phytobezoars and clogged feeding tubes. Pharmacy Newsletter. (Thomas Jefferson University Hospital) 1994;12:13.
56. Clog Zapper information. Wheeling, IL: Corpak Medsystems; 2002.
57. Guenter P. Administering medications via feeding tubes: What consultant pharmacists need to know. Consult Pharm. 1999;14:41-4, 47-8.
58. Mosby's GenRx. 11th ed. St. Louis, MO: Mosby Incorporated; 2001.
59. Medication administration. In: DeLaune SC et al, eds. Fundamentals of Nursing: Standards and Practice. 2nd ed. Clifton Park, NJ: Delmar/Thomson Learning; 2002, 673-740.
60. Administering medications. In: Potter PA, et al, eds. Basic Nursing: A Critical Thinking Approach. 4th ed. St. Louis, MO: Mosby; 1999:596-670.
61. Beckwith MC, Tyler LS, eds. Cancer Chemotherapy Manual. St. Louis, MO: Facts and Comparisons; 2001.
62. Engle KK, Hannawa TE. Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition. Am J Health Syst Pharm. 1999;56:1441-4.